Risks of cardio-vascular diseases among highly active antiretroviral therapy (HAART) treated HIV seropositive volunteers at a treatment centre in Lagos, Nigeria

Abstract

INTRODUCTION: Highly active antiretroviral therapy (HAART) has led to a decline in HIV-induced morbidity and mortality in recent years. However, it has been opined that this has led to elevated risks of cardiovascular diseases (CVDs). This study assessed the risks of CVDs among HAART experienced individuals living with HIV. METHODS: a cross sectional study involving 196 adults consisting of 118 HAART experienced and 78 HAART naïve was conducted. Anthropometric and blood pressure measurements were recorded for all participants. Blood samples obtained from the volunteers were used to determine glucose, creatinine, HIV viral load, CD4 count and lipid profile using standard methods. Lipid ratios, atherogenic indices and QRISK3 risk score were calculated. RESULTS: the median CD4 lymphocyte, mean body mass index (BMI) and HDL-c in HAART experienced participants were higher (P=0.05) than HAART naive individuals. The QRISK3 risk score and creatinine were higher (p=0.05) among HAART experienced group. In HAART experienced group, the risk of hypertension, increased low-density lipoprotein (LDL-c), atherogenic index of plasma (AIP) and QRISK3 were 3.7, 2.0, 2.38 and 3.85 times (p=0.05) higher respectively than in HAART naive. Atherogenic coefficient (AC) increase was more prevalent among male (p=0.05) participants. Risk of chronic renal disease (eGFR), hypertension and CVD (as measured by QRISK3) was higher (p=0.05) among the female and older participants respectively.

Keywords

• cardiovascular disease
• haart
• dyslipidemia
• cardiac risk ratio (crr)
• qrisk3